RT @ChrisLacoursier: #CNBC $NWBO we are now at 3 years past the last patients surgery @NorthwestBio #Glioblastoma P3 trial this trial will…
RT @ChrisLacoursier: #CNBC $NWBO we are now at 3 years past the last patients surgery @NorthwestBio #Glioblastoma P3 trial this trial will…
Adam please explain how these patients are living longer !! If the previous SOC getting better or IS IT DC VAX
@BrianRockell @Dereklowe @braintumourrsch @BrainTumourOrg Yes Brian, and I have told you NICE will not give it it's blessing if 1. It does not work 2. It is not value for money. What is becoming quite obvious is you keep trying to promote some article fro
@arieltorrres with your boyfriends parents: https://t.co/IxCIl9tQvo. This
RT @sentimentstock: Look at that long list of 69 distinguished neurosurgeons on this comprehensive article for the 2017 interim blinded dat…
First results on survival from a large Phase 3 clinical trial of an #autologous #DendriticCell #vaccine in newly diagnosed #glioblastoma https://t.co/fC1qOlAlxL | via @biomedcentral
RT @NIHBrainTumor: *Corrected: Our neuro-oncology journal club includes point and counterpoint discussions on published research. Today, Dr…
RT @NIHBrainTumor: *Corrected: Our neuro-oncology journal club includes point and counterpoint discussions on published research. Today, Dr…
RT @NIHBrainTumor: *Corrected: Our neuro-oncology journal club includes point and counterpoint discussions on published research. Today, Dr…
RT @NIHBrainTumor: *Corrected: Our neuro-oncology journal club includes point and counterpoint discussions on published research. Today, Dr…
RT @CraigHorbinski: Wow, check this out. Still preliminary, but the durations of survival are pretty doggone impressive! #glioma #BrainTumo…
RT @NIHBrainTumor: *Corrected: Our neuro-oncology journal club includes point and counterpoint discussions on published research. Today, Dr…
This was awesome! Great discussion by leaders in the field on results, limitations , and important of the yet to be published primary outcome result. #BTSM https://t.co/BGe9YYTNOS
RT @CraigHorbinski: Wow, check this out. Still preliminary, but the durations of survival are pretty doggone impressive! #glioma #BrainTumo…
RT @NIHBrainTumor: *Corrected: Our neuro-oncology journal club includes point and counterpoint discussions on published research. Today, Dr…
*Corrected: Our neuro-oncology journal club includes point and counterpoint discussions on published research. Today, Drs. Brett Theeler and @EKNduom discussed a study on the survival of newly diagnosed #glioblastoma patients: https://t.co/j127xEBPKs #Brai
RT @herkyleese: https://t.co/FnnKvQbDDC $nwbo #UCLA treatment for #gbm has not changed drastically for nearly 3 decades. 69 authors (to…
RT @herkyleese: https://t.co/FnnKvQbDDC $nwbo #UCLA treatment for #gbm has not changed drastically for nearly 3 decades. 69 authors (to…
RT @herkyleese: https://t.co/FnnKvQbDDC $nwbo #UCLA treatment for #gbm has not changed drastically for nearly 3 decades. 69 authors (to…
RT @herkyleese: https://t.co/FnnKvQbDDC $nwbo #UCLA treatment for #gbm has not changed drastically for nearly 3 decades. 69 authors (to…
RT @herkyleese: https://t.co/FnnKvQbDDC $nwbo #UCLA treatment for #gbm has not changed drastically for nearly 3 decades. 69 authors (to…
RT @herkyleese: https://t.co/FnnKvQbDDC $nwbo #UCLA treatment for #gbm has not changed drastically for nearly 3 decades. 69 authors (to…
RT @herkyleese: https://t.co/FnnKvQbDDC $nwbo #UCLA treatment for #gbm has not changed drastically for nearly 3 decades. 69 authors (to…
RT @herkyleese: https://t.co/FnnKvQbDDC $nwbo #UCLA treatment for #gbm has not changed drastically for nearly 3 decades. 69 authors (to…
https://t.co/FnnKvQbDDC $nwbo #UCLA treatment for #gbm has not changed drastically for nearly 3 decades. 69 authors (top physicians) Linda Liau Ashkan Keyoumars think they are onto something special with #dcvax safety first mild fever side effect @NIC
علاج 30% من مرضى سرطان الدماغ GBM: دراسة حديثة في مراحلها الأخيرة .. علاج جديد يعتمد على تحفيز خلايا المريض ذات الزوائد أو الخلايا التغصنية dendritic cells هذه الدراسة وصلت الى المرحلة الأخيرة بنتائج مبهره ونتمنى استمرارها للنهاية. https://t.co/EF55xBVuyu
RT @sentimentstock: @SGottliebFDA, $NWBO 's March 17 P3 #DCVax data shows that 12% of combined treatment and control patients (who cross ov…
RT @sentimentstock: @SGottliebFDA, $NWBO 's March 17 P3 #DCVax data shows that 12% of combined treatment and control patients (who cross ov…
RT @sentimentstock: @SGottliebFDA, $NWBO 's March 17 P3 #DCVax data shows that 12% of combined treatment and control patients (who cross ov…
RT @sentimentstock: @SGottliebFDA, $NWBO 's March 17 P3 #DCVax data shows that 12% of combined treatment and control patients (who cross ov…
@SGottliebFDA, $NWBO 's March 17 P3 #DCVax data shows that 12% of combined treatment and control patients (who cross over to treatment) have reached a mOS of 88.2 months or 7 years. This old data already beats $NVCR ’s Optune’s 13% survival at 5 years.
RT @sentimentstock: Looks like @woodfordfunds may actually have a very good year this year with some help from $NWBO. #GBM #DCVax-L trials…
RT @justinkeister5: This appears to be a reasonable projection comparing #DCVax to #Optune. DCVax has shown promising mOS that can do bett…
RT @justinkeister5: This appears to be a reasonable projection comparing #DCVax to #Optune. DCVax has shown promising mOS that can do bett…
RT @justinkeister5: This appears to be a reasonable projection comparing #DCVax to #Optune. DCVax has shown promising mOS that can do bett…
RT @justinkeister5: This appears to be a reasonable projection comparing #DCVax to #Optune. DCVax has shown promising mOS that can do bett…
RT @justinkeister5: This appears to be a reasonable projection comparing #DCVax to #Optune. DCVax has shown promising mOS that can do bett…
This appears to be a reasonable projection comparing #DCVax to #Optune. DCVax has shown promising mOS that can do better without side effects and an apparatus that’s worse than my son’s orthodontic headgear. @FDAOncology...paying attention? https://t.co/
RT @ChrisLacoursier: NEVER in #pharma #biotech #CNBC history has co given LOOK IN at survival efficacy EVER in any Phase 3 #oncology trial…
RT @KrstevskiBranko: This is my $NWBO DCVax-L efficacy estimate based on published P3 blended data https://t.co/aoSMffrfBq It shows this t…
RT @KrstevskiBranko: This is my $NWBO DCVax-L efficacy estimate based on published P3 blended data https://t.co/aoSMffrfBq It shows this t…
RT @KrstevskiBranko: This is my $NWBO DCVax-L efficacy estimate based on published P3 blended data https://t.co/aoSMffrfBq It shows this t…
RT @KrstevskiBranko: This is my $NWBO DCVax-L efficacy estimate based on published P3 blended data https://t.co/aoSMffrfBq It shows this t…
RT @KrstevskiBranko: This is my $NWBO DCVax-L efficacy estimate based on published P3 blended data https://t.co/aoSMffrfBq It shows this t…
RT @KrstevskiBranko: This is my $NWBO DCVax-L efficacy estimate based on published P3 blended data https://t.co/aoSMffrfBq It shows this t…
RT @KrstevskiBranko: This is my $NWBO DCVax-L efficacy estimate based on published P3 blended data https://t.co/aoSMffrfBq It shows this t…
RT @KrstevskiBranko: This is my $NWBO DCVax-L efficacy estimate based on published P3 blended data https://t.co/aoSMffrfBq It shows this t…
RT @KrstevskiBranko: This is my $NWBO DCVax-L efficacy estimate based on published P3 blended data https://t.co/aoSMffrfBq It shows this t…
RT @KrstevskiBranko: This is my $NWBO DCVax-L efficacy estimate based on published P3 blended data https://t.co/aoSMffrfBq It shows this t…
This is my $NWBO DCVax-L efficacy estimate based on published P3 blended data https://t.co/aoSMffrfBq It shows this trial has a real chance of success. $120M MC with high risk https://t.co/kXGI1SQa7T
Learn about the first set of results of a clinical trial for DCVax®-L, an autologous dendritic cell vaccine, for glioblastoma treatment. One of our own staff, Dr. Timothy Cloughesy, contributed to this study. https://t.co/aFJEZj98xd
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly... https://t.co/WfOcIFwCAo
While still preliminary dendritic vaccine (immune treatment) shows promising outcomes in #braincancer #glioblastoma. While there are critics, anything that shows the promise to help this disease with a low risk side-effect profile on top deserves attention
RT @AlMusella: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed gli…
RT @Arhdan9: @PaulDewar Hi Sir, have you tried GBM vaccine treatment called DCVax-L. https://t.co/sf6G2WJlmS https://t.co/oVPJoxFfR7 Montr…
@PaulDewar Hi Sir, have you tried GBM vaccine treatment called DCVax-L. https://t.co/sf6G2WJlmS https://t.co/oVPJoxFfR7 Montreal Neurological Institute, McGill University participated
RT @icnsInstituto: Primeros datos de vacuna terapéutica de células dendríticas en glioblastoma: pueden aumentar la supervivencia en una par…
'A #Glioblastoma Vaccine? Not Yet. https://t.co/5iN3ITjsNz… https://t.co/ZsXTtTTSJ2
RT @NatRevClinOncol: promising results of phase III study in which addition of an autologous tumor lysate-pulsed dendritic cell vaccine to…
@JohnCendpts $NWBO paper does not provide p-values and does not claim statistical significance. The analysis is unplanned and excludes progression-free survival, the primary endpoint of the trial. https://t.co/sdPj872Fta
@woodfordfunds So, you post this and choose to omit any mention of $NWBO @NorthwestBio #DCVax Truly amazing https://t.co/z4LUWVwZaf
promising results of phase III study in which addition of an autologous tumor lysate-pulsed dendritic cell vaccine to standard therapy in patients with glioblastoma https://t.co/jFkMnD5fiS
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma | Journal of Translational Medicine | Full Text https://t.co/M1JM5wY4g2
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly... https://t.co/ueJ7ja1qo6
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly... https://t.co/Zp7knRNerq #braincancer
Will Sen. McCain be a beneficiary of #RightToTry? https://t.co/lSzXkNPmzm
New vaccine has been shown to extend the life of a patient with #glioblastoma multiforme, an aggressive form of #braincancer, by as much as seven years https://t.co/TcTHOp1XHL #MSSNY
RT @icnsInstituto: Primeros datos de vacuna terapéutica de células dendríticas en glioblastoma: pueden aumentar la supervivencia en una par…
RT @celltherapy: Cue the reaction from critics and fans. $NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Tria…
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma | Journal of Translational Medicine | Full Text https://t.co/HoMiqvxTMr
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly... $NWBO https://t.co/gG6muwyKfe
RT @icnsInstituto: Primeros datos de vacuna terapéutica de células dendríticas en glioblastoma: pueden aumentar la supervivencia en una par…
RT @Sojourner618: Why is $NWBO so threatening to #Wallstreet #BigPharma and entrenched interests? Answer: DCVax-L for all operable cancers…
RT @Sojourner618: Why is $NWBO so threatening to #Wallstreet #BigPharma and entrenched interests? Answer: DCVax-L for all operable cancers…
RT @ChrisLacoursier: @JPZaragoza1 Thanks for posting pic! tomorrow #ASCO18 Industry Expert Theatre 4:15 Phase 3 trial update I hear should…
RT @Sojourner618: Why is $NWBO so threatening to #Wallstreet #BigPharma and entrenched interests? Answer: DCVax-L for all operable cancers…
RT @Sojourner618: Why is $NWBO so threatening to #Wallstreet #BigPharma and entrenched interests? Answer: DCVax-L for all operable cancers…
Why is $NWBO so threatening to #Wallstreet #BigPharma and entrenched interests? Answer: DCVax-L for all operable cancers and DCVax-Direct for all inoperable cancers. Just think about that! @DrMarcSiegel @blackrock @PaulTudorJones1 @realDonaldTrump https:/
RT @Sojourner618: @woodfordfunds Time to support $NWBO. This could be the gem that will offset your PRTA losses https://t.co/XPvuZ9fZZS h…
RT @trials4now: First results on survival from a large Phase 3 clinical trial of a vaccine in newly diagnosed #glioblastoma #childhoodcance…
RT @Sojourner618: @woodfordfunds Time to support $NWBO. This could be the gem that will offset your PRTA losses https://t.co/XPvuZ9fZZS h…
RT @Sojourner618: @woodfordfunds Time to support $NWBO. This could be the gem that will offset your PRTA losses https://t.co/XPvuZ9fZZS h…
RT @AlMusella: @SGottliebFDA #gbm Dr Gottlieb, We need access to this vaccine NOW. https://t.co/q9VD8Pggb1
RT @DBenzil: #Friday Good news! Congrats Dr. Liau! @neurosurgery First results on survival from a large Phase 3 clinical trial of an autolo…
RT @DBenzil: #Friday Good news! Congrats Dr. Liau! @neurosurgery First results on survival from a large Phase 3 clinical trial of an autolo…
RT @DBenzil: #Friday Good news! Congrats Dr. Liau! @neurosurgery First results on survival from a large Phase 3 clinical trial of an autolo…
RT @Sojourner618: @woodfordfunds Time to support $NWBO. This could be the gem that will offset your PRTA losses https://t.co/XPvuZ9fZZS h…
@woodfordfunds Time to support $NWBO. This could be the gem that will offset your PRTA losses https://t.co/XPvuZ9fZZS https://t.co/Ccqnu7Wxa6
@PaulTudorJones1 Have your analysts look at #NWBO an american company with a technology platform that will revolutionize the treatment of cancers. They need help to bring this treatment to patients and a potential multi-bagger https://t.co/Y5A6lwTGqb htt
RT @ChrisLacoursier: #Bloomberg #BBCNews @woodfordfunds #Business word is spreading around the globe #CNBC Truth will prevail. #investment…
RT @trials4now: First results on survival from a large Phase 3 clinical trial of a vaccine in newly diagnosed #glioblastoma #childhoodcance…
RT @trials4now: First results on survival from a large Phase 3 clinical trial of a vaccine in newly diagnosed #glioblastoma #childhoodcance…
First results on survival from a large Phase 3 clinical trial of a vaccine in newly diagnosed #glioblastoma #childhoodcancer #cancer #treatment https://t.co/oqmo3RXpde
Promising interim results from the DCVax-L trial for GBM. mOS even in the MGMT unmethylated group 19.8mo. Looking forward to the final results. What’s stopping us doing better right here in AUS? @SydneyCatalyst @braincancer_AU #curebraincancer https://t.co
RT @AlMusella: @SGottliebFDA #gbm Dr Gottlieb, We need access to this vaccine NOW. https://t.co/q9VD8Pggb1